Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
7.90
+0.19 (2.46%)
At close: May 20, 2025, 4:00 PM
7.98
+0.08 (1.01%)
After-hours: May 20, 2025, 6:10 PM EDT
Cullinan Therapeutics Employees
Cullinan Therapeutics had 111 employees as of December 31, 2024. The number of employees increased by 26 or 30.59% compared to the previous year.
Employees
111
Change (1Y)
26
Growth (1Y)
30.59%
Revenue / Employee
n/a
Profits / Employee
-$1,610,234
Market Cap
466.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 111 | 26 | 30.59% |
| Dec 31, 2023 | 85 | 23 | 37.10% |
| Dec 31, 2022 | 62 | 31 | 100.00% |
| Dec 31, 2021 | 31 | 7 | 29.17% |
| Dec 31, 2020 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CGEM News
- 12 days ago - Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States - GlobeNewsWire
- 27 days ago - Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - GlobeNewsWire
- 4 weeks ago - Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - PRNewsWire
- 4 months ago - Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC - Seeking Alpha